Podcasts

Join Professor Brad Rovin for an expert-led discussion focused on emerging therapies and renal outcomes in LN. This podcast will provide an overview of the effect of long-term voclosporin treatment on renal histology in patients with active LN with repeat renal biopsies and explore how BCMA-targeted CAR T-cell therapy can effectively induce disease remission in refractory LN.

Join Professors Ed Vital and Maria Dall’Era, and Doctor Guillermo J. Pons-Estel for an expert-led discussion focusing on the latest ACR 2025 SLE Guidelines. This podcast provides an overview of the latest treatment recommendations, as well as ungraded, consensus-based good practice statements that are applicable to children and adults with SLE.

Join Professors Ed Vital and Michelle Kahlenberg as they delve into the role of the cGAS pathway in systemic lupus erythematosus (SLE). This engaging discussion covers the pathway’s relevance in disease, recent clinical trial updates on cGAS inhibitors, and their potential role in the future treatment of SLE.

Join Professor Ed Vital and Doctors Reuben Benjamin, Chris Wincup, and Marc Scherlinger on the Lupus Forum in their discussion on the recent webinar “CAR-T and CAR-NK therapies: Are they the future of lupus treatment?” Watch them discuss key highlights from the webinar, including the potential of CAR-T and CAR-NK therapies as transformative treatments for lupus. Highlighting the mechanisms, applications, and the challenges of this treatment. Visit www.lupusforum.com to access the full webinar content, including detailed slide materials from Doctors Reuben Benjamin, Chris Wincup, and Marc Scherlinger.

Join Professors Ed Vital, Cynthia Aranow, Richard Furie, and Chris Edwards as they discuss the role of the JAK-STAT pathway, the emerging evidence of using JAK Inhibitors in clinical trials (SLEek trial), and the need for long-term data and the challenges faced.

Our Steering Committee Member Professor Maria Dall’Era is joined by Professor Vibeke Strand in the latest Lupus Forum podcast. Together they discuss the efficacy of belimumab treatment in patients with SLE. They will also discuss the impact of long-term anifrolumab treatment on patients’ perceived health status and health-related quality of life.